A Multicenter, Randomized, Double-blind, Placebo-controlled, Fluoxetine-referenced, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Fluoxetine-referenced, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2016

At a glance

  • Drugs Desvenlafaxine (Primary) ; Fluoxetine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Jun 2015 Top line results published in the Media Release.
    • 20 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Feb 2015 Planned number of patients changed from 390 to 333 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top